Jennison Associates LLC reduced its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 10.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 716,933 shares of the company's stock after selling 80,748 shares during the period. Jennison Associates LLC owned 1.11% of Kymera Therapeutics worth $28,842,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. Blue Trust Inc. lifted its position in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after purchasing an additional 504 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in Kymera Therapeutics by 1.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock valued at $1,649,000 after purchasing an additional 684 shares in the last quarter. KBC Group NV increased its stake in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock worth $534,000 after acquiring an additional 915 shares during the period.
Insider Buying and Selling
In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.82% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
KYMR has been the subject of a number of research analyst reports. UBS Group reduced their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Leerink Partners reiterated an "outperform" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Truist Financial reiterated a "buy" rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Guggenheim increased their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Finally, Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $55.06.
Get Our Latest Stock Report on Kymera Therapeutics
Kymera Therapeutics Stock Down 4.4 %
KYMR stock traded down $1.72 during trading on Friday, hitting $37.32. The company had a trading volume of 300,779 shares, compared to its average volume of 489,423. The firm has a market capitalization of $2.42 billion, a P/E ratio of -15.95 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52-week low of $29.24 and a 52-week high of $53.27. The company has a 50 day simple moving average of $41.46 and a 200-day simple moving average of $44.50.
Kymera Therapeutics Profile
(
Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
